Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Carboplatin (Primary) ; Pralatrexate (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2016 Results (n=50) published in the Cancer.
- 15 Jul 2016 Results published in the Cancer.
- 25 Feb 2015 Planned End Date changed from 1 Aug 2014 to 1 Jan 2018 as reported by ClinicalTrials.gov.